Evidence map›Paper›PMID 39746673›Full record

ReviewTopics in antiviral medicine2024

CROI 2024: Acute and Post-Acute COVID-19.

Annukka A R Antar, Michael J Peluso

Abstract readReview
In one paragraph

Review in Topics in antiviral medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Admission biomarkers and COVID-19 mortality: A retrospective study during Vietnam's pandemic peak.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Annukka A R AntarJohns Hopkins University, Baltimore, Maryland, USA.
Michael J PelusoUniversity of California San Francisco, San Francisco, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies of acute and post-acute COVID-19, including their biology, prevention, and treatment, were presented at the 2024 Conference on Retroviruses and Opportunistic Infections. Numerous studies reported on the impact of hybrid immunity (ie, from a combination of prior infection and vaccination) on the natural history, pathogenesis, and outcomes of infection with modern SARS-CoV-2 variants. Several studies demonstrated the continued benefit of SARS-CoV-2 vaccination and the effect of treatment, particularly in the setting of severe disease. New data regarding persistent RNA shedding in immunocompromised populations were presented, demonstrating the potential challenges that this phenomenon poses with regard to viral evolution. In addition, there was a continued focus\ on post-acute sequelae of SARS-CoV-2 including its clinical manifestations and potential underlying biology. These and other studies are summarized here.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2COVID-19 Drug TreatmentHumansImmunocompromised HostPost-Acute COVID-19 SyndromeVirus SheddingCOVID-19 Vaccines

Identifiers

PMID39746673
PMCPMC11361755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.